Centessa Pharmaceuticals plc ADR [CNTA] stock prices are up 12.52% to $16.99 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CNTA shares have gain 18.81% over the last week, with a monthly amount glided 34.84%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on July 18, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $14. Previously, Jefferies upgraded its rating to Buy on November 15, 2023, and elevated its price target to $11. On October 26, 2023, upgrade upgraded it’s rating to Equal-Weight and revised its price target to $8 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating. Guggenheim initiated its recommendation with a Buy and recommended $9 as its price target on June 12, 2023. SVB Securities started tracking with a Outperform rating for this stock on March 17, 2023, and assigned it a price target of $6. In a note dated August 12, 2022, Morgan Stanley downgraded an Underweight rating on this stock and revised its target price from $10 to $5.
The stock price of Centessa Pharmaceuticals plc ADR [CNTA] has been fluctuating between $5.15 and $17.25 over the past year. Currently, Wall Street analysts expect the stock to reach $19.5 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $16.99 at the most recent close of the market. An investor can expect a potential return of 14.77% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -22.54%, Pretax Profit Margin comes in at -22.88%, and Net Profit Margin reading is -22.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.63 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.00 points at the first support level, and at 15.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.79, and for the 2nd resistance point, it is at 18.58.
Ratios To Look Out For
It’s worth pointing out that Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA]’s Current Ratio is 13.29. As well, the Quick Ratio is 13.29, while the Cash Ratio is 4.76. Considering the valuation of this stock, the price to sales ratio is 278.28, the price to book ratio is 6.70.
Transactions by insiders
Recent insider trading involved Weinhoff Gregory M, Chief Business Officer, that happened on Sep 10 ’24 when 30000.0 shares were sold. Chief Executive Officer, SAHA SAURABH completed a deal on Sep 10 ’24 to sell 0.17 million shares. Meanwhile, Officer SAHA SAURABH bought 0.17 million shares on Sep 10 ’24.
